Our mission is to provide customers with accurate, timely, scientific information pertaining to Biogen products. We strive to exceed our customers' informational needs.
To report an adverse event
please call 1-800-456-2255.
If you have a Medical Information inquiry, please either:
Biogen, in collaboration with our partner AbbVie, has decided to voluntarily withdraw the global marketing application for daclizumab. In the United States the supply was phased out effective April 30th, 2018.
Health Care Professionals Click here to view the Dear Prescriber Letter that Biogen sent regarding the withdrawal and associated timing.
Click here to view the Dear Prescriber Letter that Biogen sent regarding immune-mediated encephalitis as an adverse drug reaction that can be related to treatment with daclizumab.